Identification of a Safe and Tolerable Carbamazepine Dosing Paradigm that Facilitates Effective Evaluation of CYP3A4 Induction

Author:

Datta‐Mannan Amita1ORCID,Shanks Elaine2,Yuen Eunice2,Jin Yan1,Rehmel Jessica1,Hall Stephen David1

Affiliation:

1. Eli Lilly and Company Indianapolis Indiana USA

2. Eli Lilly and Company Bracknell Berkshire UK

Abstract

Carbamazepine (CBZ) is the recommended alternative to rifampicin as a CYP3A4 inducer in drug–drug interaction studies. However, the traditional CBZ dosing paradigm can lead to several adverse events (AEs). This study tested a shorter CBZ dosing regimen using the CYP3A4‐sensitive index substrate midazolam (MDZ). This was a fixed‐sequence arm of an open‐label, phase I study (NCT04840888). Healthy participants (n = 15) aged 18–63 years received oral doses of 1.2 mg MDZ alone (Day 1), CBZ b.i.d. alone (100 mg Days 2–4; 200 mg Days 5–7; 300 mg Days 8–10 and 12–13), and 300 mg CBZ b.i.d. plus 1.2 mg MDZ (Days 11 and 14). One participant (6.7%) experienced constipation due to treatment with CBZ plus MDZ on Day 11. One participant (6.7%) experienced urticaria (Days 12–13), and two participants (13.3%) experienced somnolence (Days 8–10) due to treatment with 300 mg CBZ b.i.d. alone. All AEs were mild. For MDZ, the geometric mean (90% CI) ratio (vs. Day 1) of the area under the curve (AUC 0–∞) was 0.28 (0.24–0.31) on Day 11 and 0.26 (0.23–0.29) on Day 14. The AUC (0–12 hours) of CBZ was 114,000 ng∙h/mL on Day 11 and 105,000 ng∙h/mL on Day 14. Steady‐state concentrations of CBZ and induction of CYP3A4 were achieved on Day 11. The data are consistent with predictions of physiologically‐based pharmacokinetic models in Simcyp. The 9‐day dosing regimen for CBZ induction was well‐tolerated by healthy participants, supporting the use of a shorter CBZ regimen for CYP3A4 induction studies.

Publisher

Wiley

Reference30 articles.

1. Interpretation of Drug Interaction Using Systemic and Local Tissue Exposure Changes

2. Hospital admissions/visits associated with drug-drug interactions: a systematic review and meta-analysis

3. Drug interactions – principles, examples and clinical consequences;Cascorbi I.;Dtsch Arztebl Int,2012

4. FDA.Guidance for Industry: Clinical drug interaction studies – cytochrome P450 enzyme‐and transporter‐mediated drug interactions guidance for industry (2020). Accessed July 13 2023.

5. EMA.Guideline on the investigation of drug interactions (europa.eu) (2012). Accessed July 13 2023.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3